Every Form 4 that Medtronic plc (MDT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDT filings page.
Medtronic plc (MDT) reported that Harry Skip Kiil, its EVP & President Cardiovascular, sold 1,483 Ordinary Shares on September 16, 2026 in an open-market or private transaction at a reported price of $93.65 per share. Following this sale, he directly holds 42,186 Ordinary Shares of Medtronic. The filing indicates no Rule 10b5-1 trading plan was affirmed for this transaction.
Medtronic plc (MDT) reported that Chief Accounting Officer Denise L. Blomquist made a bona fide gift of 600 Ordinary Shares on September 15, 2026. The gift carried no stated per-share consideration, and Blomquist now holds 16,398 Ordinary Shares directly after the transaction. No Rule 10b5-1 trading plan is reported.
Medtronic plc (MDT) reported that executive officer Michael Marinaro, EVP, Pres MedSurg and Americas, had 1,084 Ordinary Shares withheld on 2026-08-20 to pay tax liabilities upon the vesting of previously awarded restricted stock units. After this tax-withholding disposition, he holds 116,336 Ordinary Shares directly.
Medtronic plc reports that Chief Accounting Officer Denise L. Blomquist received new equity awards and had shares withheld for taxes. On August 3, 2026 she was granted 2,337 restricted stock units vesting 100% on the third anniversary of grant, 2,337 performance share units where each unit is a contingent right to one share with performance conditions measured on April 27, 2029 over a three-year performance period (issuing 2,337 shares at target performance, up to 5,609 at maximum, and possibly 0 if minimum metrics are not met), and 1,366 stock options exercisable at $86.68 per share, vesting 25% per year and expiring August 3, 2036. On July 31, 2026, 212 shares were withheld at $85.39 per share to pay taxes on previously vested restricted stock units, and her reported holdings include 136 shares acquired through dividend reinvestment since the prior report.
Medtronic plc reported insider equity activity by SVP, Chief HR Officer Walter Matthew R. On 2026-08-03 he received 5,769 restricted stock units that vest 100% on the third anniversary of grant, 14,421 performance share units that can settle for between 0 and 34,610 shares based on performance metrics over a three-year period with conditions measured through April 27, 2029, and stock options on 40,973 ordinary shares at 86.6800 per share expiring 2036-08-03, which become exercisable 25% per year beginning one year after grant. On 2026-07-31, 1,675 ordinary shares were withheld at 85.3900 per share to satisfy tax obligations upon vesting of previously reported restricted stock units.
Medtronic EVP & President, Neuroscience Thompson Kweli received equity compensation awards, including 17,306 performance share units, 49,167 stock options with a strike price of $86.68 expiring in 2036, and 6,923 restricted stock units vesting after three years. Separately, 1,739 shares were withheld to satisfy taxes on previously vested RSUs.
Medtronic plc reported that EVP, GC and Secretary Michelle Quinn received multiple equity awards on 2026-08-03. She was granted 6,346 restricted stock units that vest in full on the third anniversary of grant and now holds 26,721 ordinary shares directly. She also received 15,863 performance share units, which can result in between 0 and 38,071 ordinary shares based on performance through April 27, 2029, and 45,070 stock options with an exercise price of 86.6800 per share, vesting 25% annually and expiring on August 3, 2036.
Medtronic EVP & Chief Financial Officer Thierry Pieton reported equity awards dated August 3, 2026, including 11,537 restricted ordinary shares, 28,842 performance share units tied to three-year performance goals, and 81,945 stock options with an $86.68 exercise price expiring in 2036.
Medtronic plc reported insider equity activity for EVP Michael Marinaro. On July 31, 2026, 3,356 ordinary shares were withheld at $85.39 per share to satisfy tax liabilities on previously vested restricted stock units. On August 3, 2026, he received grants of 10,960 and 46,147 restricted stock units with multi‑year vesting, 27,400 performance share units that can yield up to 65,760 shares based on performance, and 77,848 stock options exercisable at $86.68 per share expiring in 2036.
Medtronic plc EVP & President Cardiovascular Harry Skip Kiil received several equity awards. On August 3, 2026 he was granted 23,074 performance share units that may result in between 0 and 55,378 shares depending on three-year performance measured through April 27, 2029, 65,556 stock options with an $86.68 exercise price expiring in 2036, and 9,230 restricted stock units that vest fully on the third anniversary of grant.
On July 31, 2026, 3,074 ordinary shares were withheld at $85.39 per share to satisfy tax obligations upon the vesting of previously granted restricted stock units.
Medtronic Chairman and CEO Geoffrey Martha reported multiple equity awards. On August 3, 2026 he received 103,831 Performance Share Units, 41,533 restricted stock units, and two stock option grants for 295,002 and 273,150 shares at $86.6800 per share, with options vesting 25% annually and expiring August 3, 2036. PSU payouts can range from 0 to 249,194 shares based on performance through April 27, 2029. On July 31, 2026, 15,810 shares were withheld to cover taxes on previously vested restricted stock units.
Michelle Quinn, EVP, GC and Secretary of Medtronic plc, reported a Form 4 transaction where 2,069 Ordinary Shares were withheld to pay taxes upon the vesting of previously granted restricted stock units. After this tax-withholding disposition, she directly holds 20,375 Ordinary Shares, including 697 acquired through dividend reinvestment.
Medtronic plc senior vice president and chief HR officer Walter Matthew R. completed an open-market sale of 3,102 Ordinary Shares of Medtronic on July 8, 2026 at a price of $83.15 per share.
After this transaction, he directly owns 35,694 Ordinary Shares, so the sale represents a relatively small portion of his overall holdings. His reported holdings also include 107 shares acquired through Medtronic’s Employee Stock Ownership Plan since his prior report.
Medtronic plc executive Harry Skip Kiil reported selling Ordinary Shares in two open-market transactions. On June 8, 2026, he sold a total of 4,189 Medtronic Ordinary Shares in the open market at prices around $80.44–$80.45 per share. These are non-derivative transactions reported as direct ownership and represent routine insider sales rather than option exercises or gifts.
Medtronic plc executive Harry Skip Kiil reported a routine tax-withholding share disposition tied to equity compensation. On the transaction date, 6,817 Ordinary Shares were withheld at $83.32 per share to cover taxes upon settlement of performance-vesting restricted stock units that vested on April 24, 2026. After this non-market transaction, he directly holds 41,416 Medtronic Ordinary Shares.
Medtronic plc Chairman and CEO Geoffrey Martha reported a routine tax-related share disposition. On settlement of performance-vesting restricted stock units that vested on April 24, 2026, 41,936 ordinary shares were withheld to cover tax obligations at $83.32 per share. After this withholding, Martha directly holds 301,163 ordinary shares, and the filing does not show any open-market buying or selling.
Medtronic plc executive Michael Marinaro reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and on June 4, 2026, 7,471 Ordinary Shares were withheld at $83.32 per share to cover associated tax obligations. After this withholding, he directly holds 63,122 Ordinary Shares.
Medtronic plc senior vice president and Chief HR Officer Walter Matthew R. reported a routine tax-related share disposition. On June 4, 2026, 2,840 Ordinary Shares at $83.32 per share were withheld to cover taxes due on performance-vesting restricted stock units that vested on April 24, 2026. Following this withholding, he directly holds 38,689 Ordinary Shares.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and 237 ordinary shares were withheld to cover taxes at a value of $83.32 per share. After this withholding, she directly holds 14,737 ordinary shares of Medtronic, indicating a small adjustment to her equity position tied to compensation rather than an open-market sale.
Medtronic plc senior officer Walter Matthew R., SVP and Chief HR Officer, increased his direct equity stake through performance-based awards. On May 26, 2026, he acquired 9,149 ordinary shares via the exercise or settlement of awards and held 41,529 ordinary shares afterward.
The filing also shows the exercise of 8,449 Performance Share Units, each representing a contingent right to one Medtronic share. These units were originally granted on July 31, 2023, vested on April 24, 2026, and were settled based on performance certified on May 26, 2026. No open-market purchases or sales were reported; this reflects compensation vesting rather than trading.
Medtronic plc executive Brett A. Wall, EVP & President of Neuroscience, exercised performance-based share units that were granted on July 31, 2023. This settlement delivered 24,214 ordinary shares after performance was certified on May 26, 2026, following vesting on April 24, 2026.
After these transactions, Wall directly holds 82,183 Medtronic ordinary shares, which the disclosure notes include 527 shares acquired through dividend reinvestment since his prior report. The activity reflects compensation-related equity vesting rather than an open-market purchase or sale.
Medtronic plc Chairman and CEO Geoffrey Martha reported a compensation-related equity transaction involving performance share units. On May 26, 2026, he exercised performance-vesting share units into 85,461 Ordinary Shares, with the performance share units having fully vested on April 24, 2026. A related entry shows 94,963 Ordinary Shares credited, and his direct holdings after these transactions total 343,099 Ordinary Shares, which include 1,743 shares acquired through dividend reinvestment since his last report. Each performance share unit represented a contingent right to receive one Medtronic ordinary share, granted on July 31, 2023 and settled based on performance certified on May 26, 2026. The filing does not report any open‑market purchases or sales, only the exercise and settlement of equity awards.
Medtronic plc executive Michael Marinaro, EVP and President of MedSurg and Americas, reported the settlement of performance-based equity awards rather than an open-market trade. On May 26, 2026, he acquired 18,994 Ordinary Shares in connection with the exercise or conversion of derivative awards. These shares were issued upon settlement of performance-vesting share units that were granted on July 31, 2023, with performance certified on May 26, 2026, and that vested on April 24, 2026. Following these transactions, he directly owns 70,593 Medtronic shares.
Medtronic plc executive Harry "Skip" Kiil increased his direct Medtronic shareholding through equity compensation. On May 26, 2026, he acquired 15,195 Ordinary Shares, representing shares issued upon settlement of previously granted performance-vesting share units. These awards were granted on July 31, 2023, vested on April 24, 2026, and were settled after performance was certified on May 26, 2026. Following the transaction, Kiil directly holds 48,233 Ordinary Shares, reflecting compensation-based share delivery rather than an open-market purchase or sale.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported compensation-related share activity. On May 26, 2026, she acquired 1,712 Ordinary Shares through the exercise or settlement of derivative awards. A related Performance Share Unit award covering 1,621 units converted into Ordinary Shares, leaving no remaining units from that grant. Following these transactions, she directly holds 14,974 Ordinary Shares. Footnotes state that 1,027 of the shares issued from the performance-vesting units will be delivered when her employment with Medtronic ends, underscoring that this is a structured equity award rather than an open-market trade.
Medtronic plc SVP and Chief HR Officer Walter Matthew R. reported a small, routine tax-related share disposition. On the vesting of previously granted restricted stock units, 35 Ordinary Shares were withheld at $80.00 per share to cover taxes. Following this withholding, he directly holds 32,380 Ordinary Shares, which the footnotes state include 367 shares from dividend reinvestment and 191 shares acquired under Medtronic's Employee Stock Ownership Plan. This event reflects compensation and tax mechanics rather than an open-market stock sale.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported routine equity compensation activity. On April 27, 2026, she acquired 1,508 Ordinary Shares at $0.00 per share as a grant of restricted stock units that vest in three annual installments beginning one year from the grant date.
On April 28, 2026, 318 Ordinary Shares were disposed of at $81.90 per share, representing shares withheld to pay taxes upon vesting of previously granted restricted stock units, rather than an open-market sale. After these transactions, she directly owned 13,262 Ordinary Shares, including 106 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kendall J. Powell reported routine equity compensation activity. On April 27, 2026, he received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted restricted stock units vested, 207 shares of Medtronic ordinary shares were withheld at $81.90 per share to cover tax obligations rather than sold on the open market. After these transactions, Powell directly holds 51,380 ordinary shares, including 854 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Elizabeth G. Nabel reported routine equity compensation activity in company ordinary shares. She received an award of 2,111 restricted stock units, which vest on the one-year anniversary of the award date. The filing also reports 207 shares withheld to cover taxes upon the vesting of previously granted restricted stock units, a non‑market, tax-withholding disposition rather than an open-market sale. Following these transactions, she directly holds 19,584 ordinary shares, including 65 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kevin E. Lofton reported routine equity compensation activity involving Ordinary Shares. On April 27, 2026, he acquired 2,111 shares at $0.00 per share as a grant of restricted stock units that vest on the one-year anniversary of the award date.
On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon vesting of previously reported restricted stock units, a tax-withholding disposition rather than an open-market sale. Following these transactions, he directly holds 10,140 Ordinary Shares, which include 65 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Lewis Gregory P reported routine equity compensation activity. On April 27, 2026, he acquired 2,111 Ordinary Shares through a grant of restricted stock units that vest on the one-year anniversary of the award date. The position also now includes 65 shares acquired through dividend reinvestment since his last report. On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon the vesting of previously granted restricted stock units, a non-market disposition. After these transactions, he directly holds 5,754 Ordinary Shares.
Lee Joon Sup reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc reported that director Lee Joon Sup received an equity award of 1,803 ordinary shares in the form of restricted stock units. These units were granted at no cash cost and will vest on the one-year anniversary of the award date. Following this grant, Lee directly holds 1,803 ordinary shares.
Jellison William R reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director William R. Jellison received an equity award of 1,444 ordinary shares at a price of $0.00 per share. This reflects a grant or award, not an open-market purchase. Following the award, he directly owns 6,444 ordinary shares.
According to the footnote, the grant represents restricted stock units that vest on the one-year anniversary of the award date, tying the compensation to continued service over that period.
Medtronic plc director Randall J. Hogan reported routine equity compensation activity. He received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date. In a related move, 207 shares were withheld to cover tax obligations when previously granted restricted stock units vested, rather than being sold on the open market. Following these transactions, he directly holds 48,998 ordinary shares, which includes 65 shares acquired through dividend reinvestment since his last report.
Groetelaars John P reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director John P. Groetelaars received a stock award rather than buying shares on the market. He was granted 1,444 ordinary shares on a Form 4 report, at a stated price of $0.00 per share, as compensation.
The award represents restricted stock units that vest on the one-year anniversary of the grant date, so he must remain eligible through that period to receive the shares. Following this grant, his directly held position reported in this filing is 1,444 ordinary shares, reflecting a small, routine equity award for a board member.
Medtronic plc director Lidia Fonseca reported routine equity compensation activity. She received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date.
Upon vesting of previously granted restricted stock units, 207 shares were withheld to cover taxes at a price of $81.90 per share. After these transactions, she directly owns 7,644 Medtronic ordinary shares, which includes 65 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Scott C. Donnelly reported routine equity compensation activity. He received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted units vested, 207 shares were withheld at $81.90 per share to cover related tax obligations, rather than being sold on the market. Following these transactions, he directly holds 23,679 Medtronic ordinary shares, including 145 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Craig Arnold reported routine equity compensation activity involving the company’s ordinary shares. He received an award of 2,111 restricted stock units that vest on the one-year anniversary of the award date, increasing his direct holdings.
When previously granted restricted stock units vested, 207 shares were withheld to cover taxes, a non-market disposition used for tax payment rather than an open-market sale. Following these transactions, he directly owned 42,185 shares, which includes 65 shares acquired through dividend reinvestment since his last report.
Medtronic plc executive vice president and chief financial officer Thierry Pieton reported a tax-related share disposition tied to equity compensation. On the transaction date, 2,976 ordinary shares were withheld at a price of $96.71 per share to cover taxes upon the vesting of previously granted restricted stock units. After this withholding, Pieton directly held 37,574 Medtronic ordinary shares, which total includes 592 shares acquired through dividend reinvestment since his prior report.
Medtronic plc executive Harry Skip Kiil reported mixed equity transactions involving stock options and ordinary shares. On February 19, 2026, he exercised multiple stock options (rights to buy), converting them into ordinary shares at exercise prices reflected as $0.0000 per option in the derivative rows.
On the same date, he conducted several open-market sales of ordinary shares coded as "S," totaling 52,524 shares sold according to the transaction summary. Sale prices for these transactions include individual entries around $97.66 to $97.86, with a footnote stating a weighted average sale price and an actual range from $97.60 to $97.775.
Following these exercises and sales, his directly held ordinary share balance shown in the final row is 32,768 shares. A footnote also notes that this total includes 239 shares acquired through dividend reinvestment since his prior report.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a bona fide gift of 340 Ordinary Shares of Medtronic on February 20, 2026. The gift was reported at a price of $0.00 per share, indicating no consideration was received for the transfer.
Following this charitable or personal gift transaction, Blomquist’s directly held stake stands at 11,966 Ordinary Shares of Medtronic. The filing reflects a disposition of shares through gifting rather than an open-market sale or purchase.
Medtronic plc’s Chief Accounting Officer, Denise L. Blomquist, reported an automatic share withholding related to equity compensation. On 01/29/2026, 148 Ordinary Shares were withheld at $101 per share to cover taxes upon the vesting of previously reported restricted stock units.
After this tax withholding, Blomquist beneficially owns 12,306 Medtronic Ordinary Shares directly, which includes 97 shares acquired through dividend reinvestment since her last report.
Medtronic plc reported a routine insider transaction by one of its executives. The officer, listed as EVP & President Neuroscience, had 439 ordinary shares withheld on 12/15/2025 to pay taxes due when previously granted restricted stock units vested, at a price of $99.87 per share.
After this tax-withholding transaction, the reporting person directly owns 54,749 Medtronic ordinary shares. This total includes 251 shares that were acquired through dividend reinvestment since the prior report.
Medtronic executive insider reported a routine tax-related share withholding. On 12/15/2025, the company’s EVP, President MedSurg and Americas had 1,371 ordinary shares withheld at $99.87 per share to cover taxes when previously reported restricted stock units vested due to retirement eligibility. After this transaction, the executive beneficially owns 50,818 Medtronic shares, including 250 shares acquired through dividend reinvestment since the last report, all held directly.
Medtronic plc reported that its Chairman and CEO, who also serves as a director, had 1,564 ordinary shares withheld on 12/15/2025 to cover taxes due upon the vesting of previously granted restricted stock units. The transaction was coded as an “F” event and recorded at a price of $99.87 per share, indicating a tax-related withholding rather than an open-market sale. After this transaction, the reporting person beneficially owns 246,393 ordinary shares directly, which includes 832 shares acquired through dividend reinvestment since the prior report.
Medtronic plc executive reports routine tax-related share withholding. The EVP & President Cardiovascular of Medtronic plc reported a transaction dated 12/05/2025 involving 1,702 ordinary shares of Medtronic. The shares were withheld to cover taxes upon the vesting of previously granted restricted stock units, a common administrative step when equity awards vest. The transaction price listed was $101.36 per share.
After this withholding, the executive beneficially owns 34,177 Medtronic ordinary shares in direct form, which includes 264 shares acquired through dividend reinvestment since the prior report. No derivative securities transactions were reported in this filing.
Medtronic plc (MDT) reported an insider transaction by its Chief Accounting Officer. On 11/20/2025, the officer disposed of 170 ordinary shares of Medtronic stock at a reported price of $0, which is consistent with a coded gift transaction. After this transaction, the officer beneficially owned 12,357 ordinary shares.
A footnote explains that this ownership total includes 99 shares acquired through dividend reinvestment since the prior report. The filing shows no derivative securities positions for this reporting person.
Medtronic plc executive vice president for Global Operations & Supply Chain reported multiple open-market sales of company ordinary shares. On 11/19/2025, the officer sold several blocks of Medtronic stock at prices around $102 per share, reducing but not eliminating their direct stake. Following these transactions, the officer directly owned 46,016 ordinary shares.
The reported holdings also include 323 shares acquired through dividend reinvestment and 96 shares acquired under Medtronic's Employee Stock Ownership Plan since the prior report, showing ongoing participation in company equity programs alongside the sales.